Premium
Anterior segment optical coherence tomography imaging of OculusGenTM implants in trabeculectomy blebs
Author(s) -
BOEY PY,
NARAYANASWAMY A,
ZHENG CE,
TUN TA,
HTOON HM,
AUNG T
Publication year - 2009
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2009.238.x
Subject(s) - trabeculectomy , medicine , intraocular pressure , optical coherence tomography , glaucoma , bleb (medicine) , ophthalmology , implant , mitomycin c , open angle glaucoma , mean difference , surgery , confidence interval
Purpose To image blebs of phacotrabeculectomies performed with OculusgenTM implants (ProTop and MediKing Co Ltd, Taiwan) using Anterior Segment Optical Coherence Tomography (ASOCT) and compare these to mitomycin‐C (MMC) augmented phacotrabeculectomies Methods Thirty three subjects underwent phacotrabeculectomy with OculusGen implant, and 33 controls underwent phacotrabeculectomy with MMC. Blebs were imaged with ASOCT (Carl Zeiss Meditec Inc, Dublin, CA) and assessed for bleb height and area at postoperative month 1, 2 and 3 Results Mean age was similar in both groups (71.1 ±7.2 vs 69.9 ±6.8 years, p=0.67, OculusGen vs MMC). Distribution by gender and diagnosis (primary open vs closed angle glaucoma) was also similar. Mean baseline intraocular pressure (IOP) was comparable(18.4 ±4.7 vs 21.0 ±6.7mmHg, p=0.07, OculusGen vs MMC). There was no difference in mean bleb height at month 1 (1.02 ±0.34 vs 0.87 ±0.34mm, p=0.07, OculusGen vs MMC) or month 2 (0.83 ±0.26 vs 0.86 ±0.24, p=0.34), but mean bleb height at month 3 was lower in the OculusGen group (0.74 ±0.20 vs 1.00 ±0.28, p=0.00). There was no difference in mean bleb area at month 1 (2.91 ±0.54 vs 2.77 ±0.62mm2, p=0.41, OculusGen vs MMC), month 2 (3.19 ±0.54 vs 3.10 ±0.73, p=0.65) or month 3 (2.97 ±0.66 vs 3.23 ±0.59, p=0.16). Mean reduction in IOP at month 3 was greater in the MMC group (2.18 ±4.93 vs 8.00 ±7.60mmHg, p=0.00, OculusGen vs MMC). At month 3, the OculusGen implants were visible in 13/33 (39.4%) subjects. Conclusion Mean bleb height was lower in the OculusGen compared to MMC group at month 3, but mean bleb area was similar. Mean IOP reduction at month 3 was greater in the MMC group. At 3 months, OculusGen implants had not degraded in a third of eyes.